NCT05208892 is a NA clinical trial of SZMN block in Postoperative Pain, sponsored by Stanford University.

Who is sponsoring NCT05208892?

NCT05208892 is sponsored by Stanford University.

What drugs are being tested in NCT05208892?

Interventions in NCT05208892: SZMN block, SZMN block with Dexmedetomidine.

What condition does NCT05208892 study?

NCT05208892 studies Postoperative Pain, Opioid Use.

Is NCT05208892 still recruiting?

NCT05208892 is currently completed. Last updated 10 March 2026.

Last reviewed 2026-03-10 · How we verify

NCT05208892

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexmedetomidine Use in SZMN Blocks for Pediatric T&A Pain Control

Completed NA Last updated 10 March 2026

What this trial tests

NA trial testing SZMN block in Postoperative Pain in 114 participants. Completed in 31 December 2025.

Timeline

29 January 2024

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Stanford University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Enrollment	114
Start date	29 January 2024
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across United States

Drugs / interventions tested

SZMN block
SZMN block with Dexmedetomidine

Conditions studied

Postoperative Pain — all drugs for Postoperative Pain →
Opioid Use — all drugs for Opioid Use →

Sponsor

Stanford University

Who can join

Adults 6 Months to 18, any sex, with Postoperative Pain or Opioid Use. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The suprazygomatic maxillary nerve (SZMN) block is a well-established, safe and effective regional technique for pain management following cleft palate procedures. However, it has not been studied for patients undergoing tonsillectomy and adenoidectomy (T\&A) procedures. The goal of this study is to determine whether the SZMN block can be utilized to improve pain control and decrease morbidity in pediatric patients undergoing T\&A. An additional goal will be to determine whether the use of dexmedetomidine as a local anesthetic adjunct can prolong the analgesic effects of the SZMN block to cover the entire duration of pain experienced.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05208892 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 10 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05208892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing